ABSTRACT
Blood for coagulation analysis can be sampled from the arterial or venous system in intensive care units (ICU). The determination of clot microstructure and strength by fractal analysis (df) gives valuable information in a range of vascular haemostatic disease and sepsis. We aimed to determine if df could be measured equally and comparatively in arterial or venous blood, and 45 critically ill patients in an ICU were recruited. df was found to be readily measured in arterial blood with results comparable to those in venous blood and that add value of df as a potential marker of haemostasis in these patients.
ABSTRACT
BACKGROUND: Unfavourable clot microstructure is associated with adverse outcomes in ST elevation myocardial infarction (STEMI). We investigated the effect of comorbidities and anti-platelet treatment on clot microstructure in STEMI patients using fractal dimension (df), a novel biomarker of clot microstructure derived from the visco-elastic properties of whole blood. METHODS: Patients with STEMI (n = 187) were recruited sequentially receiving aspirin with Clopidogrel (n = 157) then Ticagrelor (n = 30). Patient characteristics and blood for rheological analysis obtained. We quantified df using sequential frequency sweep tests to obtain the phase angle of the Gel Point which is synonymous with the clot microstructure. RESULTS: Higher df was observed in males (1.755 ± 0.068) versus females (1.719 ± 0.061, p = .001), in patients with diabetes (1.786 ± 0.067 vs 1.743 ± 0.046, p < .001), hypertension (1.760 ± 0.065 vs 1.738 ± 0.069, p = .03) and previous MI (1.787 ± 0.073 vs 1.744 ± 0.066, p = .011) compared to without. Patients receiving Ticagrelor had lower df than those receiving Clopidogrel (1.708 ± 0.060 vs 1.755 ± 0.067, p < .001). Significant correlation with df was found with haematocrit (r = 0.331, p < .0001), low-density lipoprotein (LDL) (r = 0.155, p = .046) and fibrinogen (r = 0.182, p = .014). Following multiple regression analysis, diabetes, LDL, fibrinogen and haematocrit remained associated with higher df while treatment with Ticagrelor remained associated with lower df. CONCLUSIONS: The biomarker df uniquely evaluates the effect of interactions between treatment and underlying disease on clot microstructure. STEMI patients with diabetes and elevated LDL had higher df, indicating denser clot. Ticagrelor resulted in a lower df than Clopidogrel signifying a less compact clot.
Subject(s)
Percutaneous Coronary Intervention , ST Elevation Myocardial Infarction , Thrombosis , Male , Female , Humans , Ticagrelor/therapeutic use , Clopidogrel/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , ST Elevation Myocardial Infarction/drug therapy , ST Elevation Myocardial Infarction/etiology , Thrombosis/etiology , Biomarkers , Fibrinogen , Treatment Outcome , Percutaneous Coronary Intervention/adverse effectsABSTRACT
Atrial fibrillation (AF) is a major risk factor for stroke. We aim to characterize AF patients and the effects of apixaban therapy in terms of clot microstructure using gel point analysis, a novel biomarker. Seventy-eight patients were included in the study, 50 Stroke with AF (AF-S), and 28 AF without stroke (AF). Pre- and post-anticoagulation samples were collected: gel point (GP) analysis was performed to obtain (i) TGP (the time taken to reach the GP or the clot formation time) and (ii) df, the fractal dimension of the clot, a quantification of clot fibrin microstructure at the GP. At baseline, the AF-S group had a df = 1.70 (±0.05) and TGP = 306 (±73 s). The AF group had a df = 1.70 ± 0.05 and TGP = 346 ± 78 s, showing a significantly shortened TGP in the stroke group (p = .008). For both groups, apixaban significantly prolonged TGP, p = .005, but resulted in no change in df. Apixaban prolonged clotting time while having no significant impact on the blood's ability to form stable clots (no change in df ). This indicates that apixaban provides protection from the formation of thrombi by reducing clotting kinetics.
Subject(s)
Atrial Fibrillation , Stroke , Atrial Fibrillation/chemically induced , Atrial Fibrillation/complications , Atrial Fibrillation/drug therapy , Biomarkers , Humans , Pyrazoles , Pyridones/adverse effects , Stroke/drug therapy , Stroke/etiology , Stroke/prevention & controlABSTRACT
The electrochemical conversion of carbon dioxide (CO2) to useful chemical fuels is a promising route toward the achievement of carbon neutral and carbon negative energy technologies. Copper (Cu)- and Cu oxide-derived surfaces are known to electrochemically convert CO2 to high-value and energy-dense products. However, the nature and stability of oxidized Cu species under reaction conditions are the subject of much debate in the literature. Herein, we present the synthesis and characterization of copper-titanate nanocatalysts, with discrete Cu-O coordination environments, for the electrochemical CO2 reduction reaction (CO2RR). We employ real-time in situ X-ray absorption spectroscopy (XAS) to monitor Cu species under neutral-pH CO2RR conditions. Combination of voltammetry and on-line electrochemical mass spectrometry with XAS results demonstrates that the titanate motif promotes the retention of oxidized Cu species under reducing conditions for extended periods, without itself possessing any CO2RR activity. Additionally, we demonstrate that the specific nature of the Cu-O environment and the size of the catalyst dictate the long-term stability of the oxidized Cu species and, subsequently, the product selectivity.
ABSTRACT
BACKGROUND & AIMS: Cancer-associated fibroblasts (CAFs) play an important role in colorectal cancer (CRC) progression and predict poor prognosis in CRC patients. However, the cellular origins of CAFs remain unknown, making it challenging to therapeutically target these cells. Here, we aimed to identify the origins and contribution of colorectal CAFs associated with poor prognosis. METHODS: To elucidate CAF origins, we used a colitis-associated CRC mouse model in 5 different fate-mapping mouse lines with 5-bromodeoxyuridine dosing. RNA sequencing of fluorescence-activated cell sorting-purified CRC CAFs was performed to identify a potential therapeutic target in CAFs. To examine the prognostic significance of the stromal target, CRC patient RNA sequencing data and tissue microarray were used. CRC organoids were injected into the colons of knockout mice to assess the mechanism by which the stromal gene contributes to colorectal tumorigenesis. RESULTS: Our lineage-tracing studies revealed that in CRC, many ACTA2+ CAFs emerge through proliferation from intestinal pericryptal leptin receptor (Lepr)+ cells. These Lepr-lineage CAFs, in turn, express melanoma cell adhesion molecule (MCAM), a CRC stroma-specific marker that we identified with the use of RNA sequencing. High MCAM expression induced by transforming growth factor ß was inversely associated with patient survival in human CRC. In mice, stromal Mcam knockout attenuated orthotopically injected colorectal tumoroid growth and improved survival through decreased tumor-associated macrophage recruitment. Mechanistically, fibroblast MCAM interacted with interleukin-1 receptor 1 to augment nuclear factor κB-IL34/CCL8 signaling that promotes macrophage chemotaxis. CONCLUSIONS: In colorectal carcinogenesis, pericryptal Lepr-lineage cells proliferate to generate MCAM+ CAFs that shape the tumor-promoting immune microenvironment. Preventing the expansion/differentiation of Lepr-lineage CAFs or inhibiting MCAM activity could be effective therapeutic approaches for CRC.
Subject(s)
Cancer-Associated Fibroblasts/pathology , Cancer-Associated Fibroblasts/physiology , Carcinogenesis/pathology , Cell Lineage , Colorectal Neoplasms/pathology , Mesenchymal Stem Cells/physiology , Actins/genetics , Actins/metabolism , Adult , Aged , Aged, 80 and over , Animals , CD146 Antigen/genetics , CD146 Antigen/metabolism , Carcinogenesis/genetics , Carcinogenesis/metabolism , Cell Differentiation , Cell Proliferation , Colorectal Neoplasms/metabolism , Disease Models, Animal , Female , Humans , Intestinal Mucosa/pathology , Ki-67 Antigen/metabolism , Male , Mice , Mice, Transgenic , Middle Aged , Organoids/pathology , Organoids/physiology , Prognosis , Receptors, Leptin/genetics , Receptors, Leptin/metabolism , Sequence Analysis, RNA , Survival Rate , Tumor MicroenvironmentABSTRACT
AIM: Postoperative ileus (POI) is a major problem after colorectal surgery. Acetylcholinesterase inhibitors such as pyridostigmine increase gastrointestinal (GI) motility through a cholinergic anti-inflammatory pathway. The purpose of this phase II pilot study is to determine the safety of oral pyridostigmine after elective colorectal surgery. METHOD: This is a Stage 2b safety study (IDEAL framework). All adult patients undergoing elective colorectal resection or formation or reversal of stoma at the Royal Adelaide Hospital between September 2020 and January 2021 were eligible. The primary outcomes were 30-day postoperative complications, reported adverse events and GI-2 - a validated composite outcome measure of recovery of GI function after surgery, defined as the interval from surgery until first passage of stool and tolerance of a solid intake for 24 h (in whole days) in the absence of vomiting. RESULTS: Fifteen patients were included in the study. The median age was 58 (range 50-82) years and seven (47%) were men. Most participants had an American Society of Anesthesiologists grade ≥2 (53%) and the median body mass index was 27 (24-35) kg/m2 . There were 13 postoperative complications [seven were Clavien-Dindo (CD) 1, five CD 2 and one CD 3]. None appeared directly related to pyridostigmine administration, and none of the patients had any overt symptoms of excessive parasympathetic activity. Median GI-2 was 2 (1-4) days. CONCLUSION: Oral pyridostigmine appears to be safe to use after elective colorectal surgery in a select group of patients. However, considering this is a pilot study with a small sample size, larger controlled studies are needed to confirm this finding and establish efficacy for prevention of POI.
Subject(s)
Colorectal Surgery , Ileus , Aged , Aged, 80 and over , Humans , Ileus/drug therapy , Ileus/etiology , Ileus/prevention & control , Male , Middle Aged , Pilot Projects , Postoperative Complications/prevention & control , Pyridostigmine Bromide/therapeutic useABSTRACT
BACKGROUND & AIMS: Cancer-associated fibroblasts (CAFs), key constituents of the tumor microenvironment, either promote or restrain tumor growth. Attempts to therapeutically target CAFs have been hampered by our incomplete understanding of these functionally heterogeneous cells. Key growth factors in the intestinal epithelial niche, bone morphogenetic proteins (BMPs), also play a critical role in colorectal cancer (CRC) progression. However, the crucial proteins regulating stromal BMP balance and the potential application of BMP signaling to manage CRC remain largely unexplored. METHODS: Using human CRC RNA expression data, we identified CAF-specific factors involved in BMP signaling, then verified and characterized their expression in the CRC stroma by in situ hybridization. CRC tumoroids and a mouse model of CRC hepatic metastasis were used to test approaches to modify BMP signaling and treat CRC. RESULTS: We identified Grem1 and Islr as CAF-specific genes involved in BMP signaling. Functionally, GREM1 and ISLR acted to inhibit and promote BMP signaling, respectively. Grem1 and Islr marked distinct fibroblast subpopulations and were differentially regulated by transforming growth factor ß and FOXL1, providing an underlying mechanism to explain fibroblast biological dichotomy. In patients with CRC, high GREM1 and ISLR expression levels were associated with poor and favorable survival, respectively. A GREM1-neutralizing antibody or fibroblast Islr overexpression reduced CRC tumoroid growth and promoted Lgr5+ intestinal stem cell differentiation. Finally, adeno-associated virus 8 (AAV8)-mediated delivery of Islr to hepatocytes increased BMP signaling and improved survival in our mouse model of hepatic metastasis. CONCLUSIONS: Stromal BMP signaling predicts and modifies CRC progression and survival, and it can be therapeutically targeted by novel AAV-directed gene delivery to the liver.
Subject(s)
Bone Morphogenetic Proteins/metabolism , Colorectal Neoplasms/pathology , Immunoglobulins/metabolism , Intercellular Signaling Peptides and Proteins/metabolism , Liver Neoplasms/secondary , Adult , Aged , Aged, 80 and over , Animals , Cancer-Associated Fibroblasts/metabolism , Carcinogenesis/pathology , Cell Differentiation , Cell Line, Tumor , Colorectal Neoplasms/mortality , Disease Progression , Female , Hepatocytes/metabolism , Humans , Immunoglobulins/genetics , Kaplan-Meier Estimate , Male , Mice , Middle Aged , Prognosis , Signal Transduction , Tumor Microenvironment , Up-Regulation , Xenograft Model Antitumor AssaysABSTRACT
INTRODUCTION: This aim of this study is to investigate the individual effects of varying concentrations of thrombin and fibrinogen on clot microstructure (characterised through the fractal dimension of the incipient clot network, df) and clot formation time (TGP) using a fibrin-thrombin clot model. df and TGP markers are measured using a haemorheological method that has already been investigated for whole blood. METHODS: This is an in vitro study using three thrombin concentrations (0.1, 0.05 and 0.02 NIH/ml) and two fibrinogen concentrations (8âmg/ml and 12âmg/ml) to investigate a fibrin-thrombin clot model. The haemorheological changes were measured at the gel point using df and TGP. RESULTS: Fractal dimension (df) increased with increasing concentrations of thrombin both at 8âmg/ml (1.60±0.024, 1.67±0.022, 1.74±0.079) and 12âmg/ml fibrinogen concentrations (1.63±0.02, 1.87±0.019, 1.95±0.014). On the other hand, TGP decreased for both 8âmg/ml (1089±265, 637±80, 223±22 seconds) and 12âmg/ml fibrinogen concentrations (2008±247, 776±20, 410±20 seconds). In contrast to previous studies investigating whole blood, TGP increased with higher fibrinogen levels. CONCLUSIONS: The findings from this fibrin-thrombin clot model confirmed that df and TGP can detect changes in the incipient clot following manipulation of fibrinogen and thrombin concentration. df increases (indicating stronger clot) with higher concentrations of thrombin and fibrinogen. On the other hand, TGP decreased as expected with higher thrombin level but not with higher fibrinogen concentrations.
Subject(s)
Blood Coagulation Tests/methods , Blood Coagulation/drug effects , Fibrin/metabolism , Thrombin/metabolism , Thrombosis/physiopathology , HumansABSTRACT
BACKGROUND: The long term benefits of exercise on the cardiovascular status of a patient have been proven, however, their benefit/risk relationship with exercise intensity is unclear. Furthermore, many thromboembolic diseases such as myocardial infarction and ischaemic stroke are associated with profound catecholamine release. In this study we explore the relationship between catecholamine release and hemodynamic changes and their effect on coagulation. MATERIALS AND METHODS: Twelve healthy recreationally active males were recruited. Local anesthesia was given and catheters were placed under aseptic conditions, in the femoral artery and vein of the experimental leg. The first experiment involved tyramine infusion into the femoral artery at a dose of 1.0⯵mol·min-1·Lâ¯legâ¯volume-1. The second experiment involved single leg knee-extensor exercise performed at 30â¯W for 15â¯min. Venous blood was collected at each time point to assess clot microstructure using the df biomarker. RESULTS AND CONCLUSIONS: Tyramine infusion causes a local noradrenaline release in the leg. The increase in noradrenaline was associated with a significant increase in clot microstructure formation (df increased from 1.692⯱â¯0.029 to 1.722⯱â¯0.047, pâ¯=â¯0.016). Additionally moderate intensity single leg knee extensor exercise, which minimally alters sympathetic activity, also induced an increases in df (from 1.688⯱â¯0.025 to 1.723⯱â¯0.023, pâ¯=â¯0.001). This suggests that exercise can alter clot microstructure formation both via an increase in catecholeamine levels and by factors related to muscle activity per se, such as increased blood flow and consequent shear. These findings have implications for recommendations of exercise in patients at risk of cardiovascular events.
Subject(s)
Blood Coagulation Tests/methods , Blood Coagulation/drug effects , Exercise/physiology , Hemodynamics/physiology , Regional Blood Flow/drug effects , Tyramine/physiology , Humans , Regional Blood Flow/physiology , Young AdultABSTRACT
Despite the interwoven nature of platelet activation and the coagulation system in thrombosis, few studies relate both analysis of protein and cellular parts of coagulation in the same population. In the present study, we use matched ex vivo samples to determine the influences of standard antiplatelet therapies on platelet function and use advanced rheological analyses to assess clot formation. Healthy volunteers were recruited following fully informed consent then treated for 7 days with single antiplatelet therapy of aspirin (75 mg) or prasugrel (10 mg) or with dual antiplatelet therapy (DAPT) using aspirin (75 mg) plus prasugrel (10 mg) or aspirin (75 mg) plus ticagrelor (90 mg). Blood samples were taken at day 0 before treatment and at day 7 following treatment. We found that aspirin plus prasugrel or aspirin plus ticagrelor inhibited platelet responses to multiple agonists and reduced P-selectin expression. Significant platelet inhibition was coupled with a reduction in fractal dimension corresponding to reductions in mean relative mass both for aspirin plus prasugrel (-35 ± 16% change, p = 0.04) and for aspirin plus ticagrelor (-45 ± 14% change, p = 0.04). Aspirin alone had no effect upon measures of clot structure, whereas prasugrel reduced fractal dimension and mean relative mass. These data demonstrate that platelets are important determinants of clot structure as assessed by fractal dimension (df) and that effective platelet inhibition is associated with a weaker, more permeable fibrin network. This indicates a strong association between the therapeutic benefits of antiplatelet therapies and their abilities to reduce thrombus density that may be useful in individual patients to determine the functional relationship between platelet reactivity, eventual clot quality, and clinical outcome. df could represent a novel risk stratification biomarker useful in individualizing antiplatelet therapies.
Subject(s)
Blood Coagulation/drug effects , Blood Platelets/metabolism , Platelet Activation/drug effects , Thrombosis/metabolism , Female , Fractals , Humans , MaleABSTRACT
Nanoparticle metal oxide photocatalysts are attractive because of their increased reactivity and ease of processing into versatile electrode formats; however, their preparation is cumbersome. We report on the rapid bulk synthesis of photocatalytic nanoparticles with homogeneous shape and size via the cathodic corrosion method, a simple electrochemical approach applied for the first time to the versatile preparation of complex metal oxides. Nanoparticles consisting of tungsten oxide (H2WO4) nanoplates, titanium oxide (TiO2) nanowires, and symmetric star-shaped bismuth vanadate (BiVO4) were prepared conveniently using tungsten, titanium, and vanadium wires as a starting material. Each of the particles were extremely rapid to produce, taking only 2-3 min to etch 2.5 mm of metal wire into a colloidal dispersion of photoactive materials. All crystalline H2WO4 and BiVO4 particles and amorphous TiO2 were photoelectrochemically active toward the water oxidation reaction. Additionally, the BiVO4 particles showed enhanced photocurrent in the visible region toward the oxidation of a sacrificial sulfite reagent. This synthetic method provides an inexpensive alternative to conventional fabrication techniques and is potentially applicable to a wide variety of metal oxides, making the rapid fabrication of active photocatalysts with controlled crystallinity more efficient.
ABSTRACT
The electrochemical reduction of CO2 into fuels has gained significant attention recently as source of renewable carbon-based fuels. The unique high selectivity of copper in the electrochemical reduction of CO2 to hydrocarbons has called much interest in discovering its mechanism. In order to provide significant information about the role of oxygen in the electrochemical reduction of CO2 on Cu electrodes, the conditions of the surface structure and the composition of the Cu single crystal electrodes were controlled over time. This was achieved using pulsed voltammetry, since the pulse sequence can be programmed to guarantee reproducible initial conditions for the reaction at every fraction of time and at a given frequency. In contrast to the selectivity of CO2 reduction using cyclic voltammetry and chronoamperometric methods, a large selection of oxygenated hydrocarbons was found under alternating voltage conditions. Product selectivity towards the formation of oxygenated hydrocarbon was associated to the coverage of oxygen species, which is surface-structure- and potential-dependent.
ABSTRACT
OBJECTIVES: Changes in clot microstructure are increasingly implicated in the pathology of atherosclerosis although most data are from techniques in the remote laboratory using altered blood. We validate the novel biomarker Gel Point in STEMI patients and assess therapeutic interventions. Gel Point marks the transition of blood from a visco-elastic liquid to visco-elastic solid and is rapidly measured using unadulterated blood. The Gel Point provides measurements of three parameters to reflect clot microstructure (fractal dimension (df)), real-time clot formation time (TGP) and blood clot strength (elasticity at the Gel Point (G'GP)). METHODS: We prospectively recruited 38 consecutive patients with STEMI undergoing primary percutaneous coronary intervention (pPCI). Venous blood samples were collected on admission, after pPCI and 24 h after admission for assessment of the new biomarkers, standard coagulation tests and scanning electron microscopy (SEM). RESULTS: df after pPCI was lower than df on admission (mean 1.631 [SD 0.063] vs 1.751 [0.052], p < 0.000001) whereas df at 24 h was similar to that on admission. G'GP also showed similar trend to df (p < 0.001). TGP was prolonged at after-PCI measurement compared with admission (median 854 s [IQR 581-1801] vs 217 [179-305], p < 0.00001). Changes in the values of df and G'GP were consistent with changes in the SEM images of the mature clot. CONCLUSIONS: We characterise Gel Point derived markers of clot microstructure in patients admitted with emergency arterial thrombosis. This point of care test can potentially be used to assess the efficacy of therapeutic interventions by measuring changes in clot microstructure.
Subject(s)
Blood Coagulation Tests/methods , Blood Coagulation , Coronary Thrombosis/diagnosis , Fractals , Myocardial Infarction/diagnosis , Point-of-Care Testing , Aged , Aged, 80 and over , Anticoagulants/therapeutic use , Blood Coagulation/drug effects , Coronary Angiography , Coronary Thrombosis/blood , Coronary Thrombosis/therapy , Elasticity , Feasibility Studies , Female , Fibrinolytic Agents/therapeutic use , Humans , Male , Microscopy, Electron, Scanning , Middle Aged , Myocardial Infarction/blood , Myocardial Infarction/therapy , Percutaneous Coronary Intervention , Platelet Aggregation , Platelet Aggregation Inhibitors/therapeutic use , Predictive Value of Tests , Prospective Studies , Reproducibility of Results , Time Factors , Treatment Outcome , ViscosityABSTRACT
This study compared patients with venous thromboembolism (VTE) to non-VTE patients using a biomarker of clot microstructure (df ) and clot formation time (TGP ). df was the only marker that identified a significant difference (P < 0·001) between the VTE (n = 60) and non-VTE cohorts (n = 69). The 'abnormal' clot microstructures in the VTE patients suggests either inadequate response to anticoagulant therapy or the presence of a procoagulant state not detected by other markers of coagulation (i.e., International Normalized Ratio). Furthermore, elevated values of df in first time VTE patients who later develop a secondary event indicates that df may identify those at risk of recurrence.
Subject(s)
Blood Coagulation Tests , Elasticity Imaging Techniques , Hemorheology , Venous Thromboembolism/blood , Aged , Anticoagulants/therapeutic use , Biomarkers/blood , Female , Fibrin/analysis , Fibrinolysis , Gels , Humans , Male , Middle Aged , Time Factors , Venous Thromboembolism/drug therapy , Viscoelastic Substances , Warfarin/therapeutic useABSTRACT
INTRODUCTION: We investigated the effect of progressive haemodilution on the dynamics of fibrin clot formation and clot microstructure using a novel rheological method. The technique measures clotting time (TGP), clot strength (G`GP), and quantifies clot microstructure (df) at the incipient stages of fibrin formation. We use computational modelling to examine the relationship between structure and mass, as well as helium ion microscopy (HIM) to compare morphological changes in the fully formed clot to that of the incipient clot. METHODS: This is an in vitro study; 90 healthy volunteers were recruited with informed consent and a 20ml sample of whole blood obtained from each volunteer. Five clinically relevant dilutions were investigated using 0.9w.v isotonic saline (0, 10, 20, 40 and 60%, n=18 for each dilution). The rheological method of assessing structural clot changes was compared against conventional coagulation screen and fibrinogen estimation. RESULTS: Fractal dimension (df) and final clot microstructure both decreased with progressive dilution (significant at a dilution of 20%) with similar relationships observed for final clot characteristics in HIM images. Significant correlations were observed between df and G`GP (clot strength) (0.345, p=0.02), as well as clotting time (PT: -0.690, p>0.001; APTT: -0.672, p>0.001; TGP: -0.385, p=0.006). CONCLUSIONS: This study provides new insight into the effects of haemodilution by isotonic saline on clotting time (TGP), clot strength (G'GP) and clot microstructure (df). Previous studies have attempted to link clot microstructure to clot quality/strength, however this study provides a significant step in quantifying these relationships.
Subject(s)
Blood Coagulation , Fibrin/ultrastructure , Hemodilution/methods , Biomarkers/blood , Biomarkers/metabolism , Blood Coagulation Tests , Computer Simulation , Fibrin/metabolism , Fibrinogen/metabolism , Fibrinogen/ultrastructure , Fractals , Humans , Models, Biological , Rheology/methods , Sodium Chloride/metabolismABSTRACT
BACKGROUND: Colorectal cancer surgery carries a high risk of venous thromboembolism (VTE) but the optimal duration of thromboprophylaxis is unknown. The cost-effectiveness of extended prophylaxis is not known in Australasia. The aims of this study were to determine the 30-day incidence of VTE in patients undergoing colorectal cancer surgery, to audit compliance with thromboprophylaxis protocols and to estimate the cost of treating all patients for 28 days with enoxaparin. METHODS: Patients undergoing elective colorectal cancer surgery from 2007 to 2009 at the Royal Adelaide and Queen Elizabeth hospitals were identified from a prospective database. Case note review was conducted for patient demographics, VTE risk factors, types of thromboprophylaxis used, complications, readmission rate and VTE rate. Documented compliance with unit VTE protocols was calculated. The cost of treating all patients with enoxaparin as prophylaxis for 28 days was then estimated. RESULTS: A total of 254 patients were identified. The in-hospital VTE rate was 0.79% (2 out of 254). The post-discharge VTE rate was 0.39% (1 out of 254). Compliance with thromboprophylaxis protocols was excellent. Pharmacological thromboprophylaxis was used in 97% of patients, graduated compression stockings in 84% and pneumatic compression devices in 53%. The estimated cost of extended prophylaxis for all 254 patients was $32,308.80. CONCLUSIONS: We have demonstrated excellent compliance with in-hospital thromboprophylaxis. Hence, we have low VTE rates in-particular, post-discharge VTE. The infrequency of post-discharge VTE means that the cost-effectiveness of extended prophylaxis might be questioned.
Subject(s)
Anticoagulants/administration & dosage , Colorectal Neoplasms/surgery , Enoxaparin/administration & dosage , Postoperative Complications/prevention & control , Venous Thromboembolism/prevention & control , Aged , Anticoagulants/economics , Australia/epidemiology , Clinical Protocols , Cost-Benefit Analysis , Elective Surgical Procedures , Enoxaparin/economics , Female , Humans , Intermittent Pneumatic Compression Devices/statistics & numerical data , Male , Patient Compliance , Postoperative Complications/epidemiology , Pulmonary Embolism/economics , Pulmonary Embolism/epidemiology , Pulmonary Embolism/prevention & control , Risk Factors , Venous Thromboembolism/economics , Venous Thromboembolism/epidemiology , Venous Thrombosis/economics , Venous Thrombosis/epidemiology , Venous Thrombosis/prevention & controlABSTRACT
BACKGROUND: α1(V) is an extensively modified collagen chain important in disease. RESULTS: Comprehensive mapping of α1(V) post-translational modifications reveals unexpectedly large numbers of X-position hydroxyprolines in Gly-X-Y amino acid triplets. CONCLUSION: The unexpected abundance of X-position hydroxyprolines suggests a mechanism for differential modification of collagen properties. SIGNIFICANCE: Positions, numbers, and occupancy of modified sites can provide insights into α1(V) biological properties. Aberrant expression of the type V collagen α1(V) chain can underlie the connective tissue disorder classic Ehlers-Danlos syndrome, and autoimmune responses against the α1(V) chain are linked to lung transplant rejection and atherosclerosis. The α1(V) collagenous COL1 domain is thought to contain greater numbers of post-translational modifications (PTMs) than do similar domains of other fibrillar collagen chains, PTMs consisting of hydroxylated prolines and lysines, the latter of which can be glycosylated. These types of PTMs can contribute to epitopes that underlie immune responses against collagens, and the high level of PTMs may contribute to the unique biological properties of the α1(V) chain. Here we use high resolution mass spectrometry to map such PTMs in bovine placental α1(V) and human recombinant pro-α1(V) procollagen chains. Findings include the locations of those PTMs that vary and those PTMs that are invariant between these α1(V) chains from widely divergent sources. Notably, an unexpectedly large number of hydroxyproline residues were mapped to the X-positions of Gly-X-Y triplets, contrary to expectations based on previous amino acid analyses of hydrolyzed α1(V) chains from various tissues. We attribute this difference to the ability of tandem mass spectrometry coupled to nanoflow chromatographic separations to detect lower-level PTM combinations with superior sensitivity and specificity. The data are consistent with the presence of a relatively large number of 3-hydroxyproline sites with less than 100% occupancy, suggesting a previously unknown mechanism for the differential modification of α1(V) chain and type V collagen properties.
Subject(s)
Collagen Type V/chemistry , Hydroxyproline/chemistry , Amino Acid Motifs , Amino Acid Sequence , Animals , Cattle , Collagen Type V/genetics , Collagen Type V/metabolism , Humans , Hydroxyproline/genetics , Hydroxyproline/metabolism , Mass Spectrometry , Molecular Sequence Data , Peptide MappingABSTRACT
Mass spectrometry (MS)-based phosphoproteomics remains challenging due to the low abundance of phosphoproteins and substoichiometric phosphorylation. This demands better methods to effectively enrich phosphoproteins/peptides prior to MS analysis. We have previously communicated the first use of mesoporous zirconium dioxide (ZrO(2)) nanomaterials for effective phosphopeptide enrichment. Here, we present the full report including the synthesis, characterization, and application of mesoporous titanium dioxide (TiO(2)), ZrO(2), and hafnium dioxide (HfO(2)) in phosphopeptide enrichment and MS analysis. Mesoporous ZrO(2) and HfO(2) are demonstrated to be superior to TiO(2) for phosphopeptide enrichment from a complex mixture with high specificity (>99%), which could almost be considered as a "purification", mainly because of the extremely large active surface area of mesoporous nanomaterials. A single enrichment and Fourier transform MS analysis of phosphopeptides digested from a complex mixture containing 7% of alpha-casein identified 21 out of 22 phosphorylation sites for alpha-casein. Moreover, the mesoporous ZrO(2) and HfO(2) can be reused after a simple solution regeneration procedure with comparable enrichment performance to that of fresh materials. Mesoporous ZrO(2) and HfO(2) nanomaterials hold great promise for applications in MS-based phosphoproteomics.
Subject(s)
Mass Spectrometry/methods , Metals/chemistry , Nanostructures/chemistry , Oxides/chemistry , Phosphopeptides/analysis , Amino Acid Sequence , Caseins/chemistry , Caseins/metabolism , Hafnium/chemistry , Molecular Sequence Data , Porosity , Spectroscopy, Fourier Transform Infrared , Titanium/chemistry , Trypsin/metabolism , Zirconium/chemistryABSTRACT
Here we report the first application of a fractal analysis of the viscoelastic properties of incipient blood clots. We sought to ascertain whether the incipient clot's fractal dimension, D(f,) could be used as a functional biomarker of hemostasis. The incipient clot is formed at the gel point (GP) of coagulating blood, the GP demarcating a functional change from viscoelastic liquid to a viscoelastic solid. Incipient clots formed in whole healthy blood show a clearly defined value of D(f) within a narrow range that represents an index of clotting in health, where D(f) = 1.74 (± 0.07). A significant relationship is found between the incipient clot formation time, T(GP), and the activated partial thromboplastin time, whereas the association of D(f) with the microstructural characteristics of the incipient clot is supported by its significant correlation with fibrinogen. Our study reveals that unfractionated heparin not only prolongs the onset of clot formation but has a significant effect on its fractal microstructure. A progressive increase in unfractionated heparin concentration results in a linear decrease in D(f) and a corresponding prolongation in T(GP). The results represent a new, quantitative measure of clot quality derived from measurements on whole blood samples.
Subject(s)
Blood Coagulation Disorders/diagnosis , Blood Coagulation , Thrombelastography , Adult , Aged , Anticoagulants/pharmacology , Blood Coagulation/drug effects , Blood Viscosity/drug effects , Female , Fibrinogen/metabolism , Hemorheology/drug effects , Hemostasis/drug effects , Heparin/pharmacology , Humans , Male , Middle Aged , Thrombelastography/methods , Young AdultABSTRACT
BACKGROUND: One-stop rectal bleeding clinics (RBC) are designed to diagnose and treat colorectal diseases that present with rectal bleeding. The Queen Elizabeth Hospital RBC is an open access clinic and is unique in South Australia. It offers flexible sigmoidoscopy and facilities for treating common anorectal conditions. METHODS: Data of all patients presenting to the RBC were prospectively recorded into a database. Data were collected on the patient details, presentation, medical history, physical examination, treatment and intended follow-up. RESULTS: A total of 1539 cases was seen in the clinic between March 2000 and February 2006. Flexible sigmoidoscopy was carried out in 1145 cases (75.03%). Banding or injection of haemorrhoids was carried out in 383 cases. A total of 590 patients was referred for colonoscopy and of these, 27 were diagnosed with colorectal adenocarcinoma or squamous cell cancer of the anus. Most of these patients were more than 50 years old (26 of 27; 96.30%) and had associated symptoms, such as weight loss or altered bowel habit with their rectal bleeding (23 of 27; 85.19%). CONCLUSION: Rectal bleeding clinics can facilitate early diagnosis of colorectal malignancy and can also provide a 'one-stop shop' for treating benign anorectal conditions.